We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 24, 2021

Dapagliflozin Improves Cardiovascular Outcomes in Patients With Poor Baseline Kidney Function and Type 2 Diabetes

JAMA Cardiology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Cardiology
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiol 2021 Apr 14;[EPub Ahead of Print], TA Zelniker, I Raz, O Mosenzon, JP Dwyer, HHJL Heerspink, A Cahn, EL Goodrich, K Im, DL Bhatt, LA Leiter, DK McGuire, JPH Wilding, I Gause-Nilsson, AM Langkilde, MS Sabatine, SD Wiviott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading